Pharmaceutical
- Pharmaceutical intermediates
- Heterocyclic Compound
- OLED material intermediate
- Diphenylamine intermediates
- Nutritional Supplements
- Pharmaceutical raw materials
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Urinary System Drugs
- Endocrine System
- Other
Medicine Excipients
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Hrk supply Fidaxomicin Raw materials powder
Product Overview:
fidaxomicin (Dificid), developed by Optimer, was approved by the FDA on May 27, 2011. Fedamycin is a macrolide antibiotic, which has a novel mechanism of action, mainly by inhibiting the RNA polymerase of bacteria to produce rapid anti-Clostridium difficile infection (CDI). Its treatment of CDI is superior to existing drugs. The safety and efficacy of fedamycin were validated in two large, multicenter, randomized, double-blind, controlled clinical trials. Common adverse reactions of fedamycin include nausea, vomiting, headache, stomachache and dysentery.
Hrk supply Fidaxomicin Raw materials powder Attributes
CAS:873857-62-6
MF:C52H74Cl2O18
MW:1058.04
EINECS:/
Specification: 99% min Fidaxomicin powder
Sample:Fidaxomicin powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Store at -20°C
Shelf Life: 2 Years
Test Method: HPLC
Hrk supply Fidaxomicin Raw materials powder Details
Drug interaction of Fidaxomicin powder.
Fedamicin and its major metabolite, OP-1118, are substrates for P-glycoprotein efflux transporters, which are present in the GI tract. The interactions of fedamicin with P-glycoprotein substrates and their inhibitors, as well as with CYP450 isoenzymes 3A4, 2C9, and 2C19 have been evaluated. The drugs studied included cyclosporin, digoxin, midazolam, omeprazole and warfarin. Although the combination of cyclosporine and fedamicin nearly tripled the maximum blood concentration of fedamicin, these changes were not clinically significant because the concentration was still in the ng/mL range. There was no change in the pharmacokinetics of fedamicin in combination with the other drugs. According to current research, fedamicin does not need to be adjusted when drugs that alter P-glycoprotein efflux transporters and cytochrome P450 isoenzymes are used simultaneously.
Uses of Fidaxomicin.
In vitro study of Fidaxomicin.
Fidaxomicin inhibits RNA polymerase by binding to the DNA template-RNA polymerase (RNAP) complex before the open RNAP-DNA complex is formed, that is, before transcription begins. As a result, it inhibits protein synthesis. As a result, apoptosis is triggered in susceptible organisms such as C.difficile.
Product Methods of Bulk Fidaxomicin powder.
